SumanKambhampatiMD

PubMed

• -class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
  Robert M Rifkin, Caitlin L Costello, Ruemu E Birhiray, Suman Kambhampati, Joshua Richter, Rafat Abonour, Hans C Lee, Michael Stokes, Kaili Ren, Dawn Marie Stull, Dasha...> ;Future Oncology. 2024 Jan 1
• 1 citations
  In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
  Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati, Sudhir Manda, Roger M Lyons, Habte A Yimer, Dasha Cherepanov, Eric Lloyd, Pres...> ;Blood Cancer Journal. 2023 Sep 19
• 2 citations
  Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...
  Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, ...> ;Journal of Clinical Oncology. 2023 Nov 1
• 1 citations
  Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
  Gonzalez-Lugo, J., Kambhampati, S., Yacoub, A., Donnellan, W., Berdeja, J., Bhagat, P., Fehn, K., Remy, C., Jasra, S., Kazemi, M., Pradhan, K., Kim, M., Mantzaris, I.,...> ;Clinical Cancer Research. 2023 Jan 4
• 41 citations
  Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
  Lionel Adès, Larisa Girshova, Vadim A Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argir...> ;Blood Advances. 2022 Sep 13
• A Primer on Chimera Associated Receptor T-Cells.
  Sumalatha Muthineni, Katelyn Zink, Suman Kambhampati> ;Missouri Medicine. 2021 Sep 1
• 18 citations
  Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019.
  Nicole Balmaceda, Muhammad Aziz, Viveksandeep Thoguluva Chandrasekar, Brian McClune, Suman Kambhampati, Leyla Shune, Al-Ola Abdallah, Faiz Anwer, Aneela Majeed, Muzaff...> ;BMC Cancer. 2021 Jun 26
• 7 citations
  Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myel...
  Pinkal Desai, Janice M. Brown, Saar Gill, Melham M. Solh, Luke P. Akard, Jack W. Hsu, Celalettin Ustun, Charalambos Andreadis, Olga Frankfurt, James M. Foran, John Lis...> ;Journal of Clinical Oncology. 2021 Jun 22
• 29 citations
  Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
  Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Ch...> ;Blood. 2021 May 20
• 25 citations
  Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
  Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Suman Kambhampati, John M. Burke, Frederick Lansigan, Marshall T. Schreeder...> ;The Lancet. Haematology. 2021 Apr 1
• 6 citations
  Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
  Ghulam Rehman Mohyuddin, Kelly Koehn, Leyla Shune, Muhammad Aziz, Al-Ola Abdallah, Brian McClune, Siddhartha Ganguly, Joseph P. McGuirk, Suman Kambhampati> ;Leukemia & Lymphoma. 2021 Jan 8
• 17 citations
  pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
  Priyanka Ray, Debasmita Dutta, Inamul Haque, Gauthami Nair, Jiyan Mohammed, Meredith Parmer, Narendra Kale, Megan Orr, Pooja Jain, Snigdha Banerjee, Katie M. Reindl, S...> ;Molecular Pharmaceutics. 2021 Jan 4
• 8 citations
  Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
  Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak, Veena Charu, Roger M. Lyons, Jack Aiello, Kimberly Bogard, Renda H. Ferrari, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 1
• 2 citations
  Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better.
  Ghulam Rehman Mohyuddin, Saqib Abbasi, Jacob Ripp, Anurag K. Singh, Suman Kambhampati, Brian McClune> ;Leukemia & Lymphoma. 2020 Jun 18
• 1 citations
  Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient ...
  Saqib Abbasi, Alec Britt, Brian McClune, Leyla Shune, Suman Kambhampati, Ghulam Rehman Mohyuddin> ;Leukemia & Lymphoma. 2020 Feb 7
• 24 citations
  CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
  Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha Gunewardena, Daniel D. Von Hoff, Sanku Mal...> ;Molecular Cancer Therapeutics. 2019 Jan 1
• 5 citations
  Comparison of Bone Marrow Biopsy Specimens Obtained Using a Motorized Device and Manual Biopsy Systems
  Catherine Glennon, Janet M Woodroof, Suman Kambhampati, Alexis C Battershell, Serena R O'Connor, Kiley B Roberts> ;Asia-Pacific Journal of Oncology Nursing. 2018 Oct 1
• 17 citations
  CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
  Guillermo Garcia-Manero, Bart L. Scott, Christopher R. Cogle, Thomas E. Boyd, Suman Kambhampati, Joel Hetzer, Qian Dong, Keshava Kumar, Stacey M. Ukrainskyj, C.L. Beac...> ;Leukemia Research. 2018 Sep 1
• 4 citations
  Positivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA.
  John L. Park, Veronica McPike, Suman Kambhampati, Chao Huang, January Fields-Meehan, Linda Verkruyse, Ace Allen, Eashwer Reddy> ;Federal Practitioner. 2018 Aug 1
• 32 citations
  The MAZ transcription factor is a downstream target of the oncoprotein Cyr61/CCN1 and promotes pancreatic cancer cell invasion via CRAF-ERK signaling.
  Gargi Maity, Inamul Haque, Arnab Ghosh, Gopal Dhar, Vijayalaxmi Gupta, Sandipto Sarkar, Imaan Azeem, Douglas H. McGregor, Abhishek Choudhary, Donald R. Campbell, Suman...> ;The Journal of Biological Chemistry. 2018 Mar 23
• 40 citations
  Leptin-induced ER-α-positive breast cancer cell viability and migration is mediated by suppressing CCN5-signaling via activating JAK/AKT/STAT-pathway.
  Inamul Haque, Arnab Ghosh, Seth Acup, Snigdha Banerjee, Kakali Dhar, Amitabha Ray, Sandipto Sarkar, Suman Kambhampati, Sushanta K. Banerjee> ;BMC Cancer. 2018 Jan 25
• 8 citations
  Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS).
  Brea Lipe, Suman Kambhampati, Peter J. Van Veldhuizen, Abdulraheem Yacoub, Omar S. Aljitawi, Joseph R. Mikhael> ;Blood Cancer Journal. 2017 Dec 14
• 18 citations
  Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute ...
  Bruno C. Medeiros, Kelly McCaul, Suman Kambhampati, Daniel A. Pollyea, Rajat Kumar, Lewis R. Silverman, Andrea Kew, Lalit Saini, C.L. Beach, Ravi Vij, Xiwei Wang, J. Z...> ;Haematologica. 2018 Jan 1
• 55 citations
  Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation
  Tushar D. Bhagat, Si Chen, Matthias Bartenstein, A. Trevor Barlowe, Dagny Von Ahrens, Gaurav Choudhary, Patrick Tivnan, Elianna M. Amin, A. Mario Marcondes, Mathijs A....> ;Cancer Research. 2017 Sep 15
• 39 citations
  A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
  Gregory A. Reed, Gary J. Schiller, Suman Kambhampati, Martin S. Tallman, Dan Douer, Mark D. Minden, Karen W.L. Yee, Vikas Gupta, Joseph Brandwein, Yulia Jitkova, Marce...> ;Cancer Medicine. 2016 Nov 1
• Join now to see all

Abstracts/Posters

• Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Inpatient HospitalizationÍs Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient...
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study
  Suman Kambhampati, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018